Full Year Report 2007
Integration of SCHWARZ PHARMA Business into UCB Group on Target
For more information, please see our website: http://www.schwarzpharma.com/sp/n192/Interim_Reports/
This press release contains assumptions, expectations, and forecasts on future sector trends, on future legal and commercial developments, and on the future development of the company. These assumptions, expectations, and forecasts are no guarantee for future performance and are subject to change at any time. Consequently, future reports and the factual circumstances of the company may deviate materially from the outlook presented by the above. The company assumes no responsibility for updating such assumptions, expectations, and forecasts on future sector trends, on future legal and commercial developments, and on the future development of the company.
UCB Pharma GmbH
SCHWARZ PHARMA AG (seated in Monheim, Germany) is a company of the UCB Group, Brussels/Belgium (www.ucb-group.com). UCB is listed on the Euronext exchange in Brussels and holds around 89% of all SCHWARZ PHARMA shares.
UCB is a leading global biopharmaceutical company whose focus is on researching, developing, and commercializing innovative pharmaceutical and biotechnological products in the fields Central Nervous System, allergic and respiratory diseases, immunological and inflammatory diseases, and oncology. UCB achieved sales of €3.6 billion (pro forma) in 2007 and employs more than 11.000 workers in 40 countries.